Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
16 Dec, 20:00
NYSE NYSE
$
1,054. 29
-7.9
-0.74%
After Hours
$
1,052. 20
-2.09 -0.2%
992.01B Market Cap
104.2 P/E Ratio
5.2% Div Yield
4,009,404 Volume
6.64 Eps
$ 1,062.19
Previous Close
Day Range
1,036.32 1,068.23
Year Range
623.78 1,111.99
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 51 days
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?

Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks | 1 year ago
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.

Reuters | 1 year ago
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Lilly's Alzheimer's drug approved in the UK

Lilly's Alzheimer's drug approved in the UK

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.

Reuters | 1 year ago
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock

This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock

Fewer contenders means fewer constraints on expanding market share.

Fool | 1 year ago
Lilly sues online vendors, medical spa over copycat weight-loss drugs

Lilly sues online vendors, medical spa over copycat weight-loss drugs

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.

Reuters | 1 year ago
Eli Lilly Buy On Weakness Signal (Technical Analysis)

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Eli Lilly has triggered multiple Buy signals, including Timing, SAR, and Fundamental, with a 12-month target of ~$1,150. Technical indicators like Full Stochastic, Chaikin money flow, and ADX Demand signal show bullish trends and outperformance versus the Index. Despite strong Growth, Momentum, and Profitability scores, poor Valuation and Revision scores make LLY risky, leading to potential selling on good news.

Seekingalpha | 1 year ago
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now

1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now

Eli Lilly just secured a huge win, and it's not related to the weight loss industry.

Fool | 1 year ago
Lilly Loses Around $14B This Week: How to Play LLY Stock

Lilly Loses Around $14B This Week: How to Play LLY Stock

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

Zacks | 1 year ago
2 High-Flying Growth Stocks With Massive Upside Potential

2 High-Flying Growth Stocks With Massive Upside Potential

These innovative drugmakers have potential catalysts ahead.

Fool | 1 year ago
This is Huge News For Eli Lilly Investors

This is Huge News For Eli Lilly Investors

Eli Lilly is investing billions into new research and manufacturing capabilities.

Fool | 1 year ago
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon

3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Fool | 1 year ago
Loading...
Load More